SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Sarepta Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMO Products [Member] | $230.56M | $228.55M | $259.21M | $238.55M | $231.27M | $236.54M | $254.01M | $248.79M | $238.83M | $225.55M | $233.82M | $240.21M | 57.5% | -0.3% |
| ELEVIDYS [Member] | $98.13M | $101.97M | $110.40M | $131.50M | $281.85M | $374.99M | $384.15M | $180.98M | $121.72M | $359.48M | $131.25M | $69.11M | 24.5% | -65.2% |
By region
From the segment and revenue-disaggregation notes of Sarepta Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.